Form 4: Exelixis Director David Johnson Granted Stock Options Under 2017 Equity Plan

Exelixis, Inc. director David Edward Johnson was granted 21,464 stock options with an exercise price of $42.60, vesting fully on the first anniversary of the grant date.

Summary

• David Edward Johnson, a Director of Exelixis, Inc. (EXEL), was granted 21,464 options to purchase common stock.
• The options were granted on May 29, 2025, under the Exelixis, Inc. 2017 Equity Incentive Plan.
• The exercise price for these options is $42.60 per share.
• The options are immediately exercisable, subject to repurchase provisions, and will vest 100% on May 29, 2026, contingent on Mr. Johnson's continuous service.
• The options have an expiration date of May 28, 2032.
• Mr. Johnson is deemed to hold these securities for the benefit of Caligan Partners Master Fund LP and managed accounts for which Caligan Partners LP serves as investment manager.

Sentiment

Score: 5

Explanation: The document reports a standard insider transaction (option grant) which is neutral in sentiment. It reflects ongoing compensation practices without indicating significant positive or negative operational or financial news.

Positives

• The grant of stock options aligns the interests of Director David Johnson with those of shareholders, incentivizing long-term performance.
• The options are granted under an existing and approved equity incentive plan (2017 Equity Incentive Plan), indicating standard corporate governance practices.

Negatives

• The exercise of these options in the future could lead to a minor dilution of existing shareholder equity, though this is a standard aspect of equity compensation plans.

Risks

• The vesting of the options is subject to Mr. Johnson's continuous service through the vesting date (May 29, 2026), meaning the options could be forfeited if service ceases before then.

Future Outlook

The options granted to Director David Johnson are set to vest 100% on May 29, 2026, contingent upon his continued service to the company, providing a future incentive for his role.

Management Comments

• "Option granted to David Johnson ('Mr. Johnson') pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 100% of the shares subject to the option on the first anniversary of the date of grant, subject to Mr. Johnson's continuous service through such date."
• "Mr. Johnson is deemed to hold the securities reported herein for the benefit of Caligan Partners Master Fund LP (the 'Caligan Master Fund') and managed accounts to which Caligan Partners LP ('Caligan') serves as investment manager (the 'Caligan Accounts', together with the Caligan Master Fund, the 'Caligan Fund and Accounts'), and may, after vesting, if applicable, transfer the securities directly to the Caligan Fund and Accounts."
• "Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."
• "Caligan may be deemed to be a director by deputization of the Issuer by virtue of the fact that Mr. Johnson currently serves on the Issuer's board of directors."

Industry Context

This Form 4 filing represents a routine insider transaction, specifically an equity grant to a director, which is a common practice across industries to align management and board interests with shareholder value. It does not provide broader industry trends or competitive insights.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is a standard practice in the biotechnology and pharmaceutical industries, similar to companies like Amgen (AMGN) or Gilead Sciences (GILD), which frequently use equity awards to incentivize their board members and executives.
• The vesting schedule (100% on first anniversary) is a common structure for director equity grants, aiming to retain board members and ensure their commitment over at least a year.

Corporate Governance

Related Party Transactions

• The option grant to David Johnson, a director, is a transaction with a related party. Furthermore, Mr. Johnson is deemed to hold these securities for the benefit of Caligan Partners Master Fund LP and Caligan Accounts, with Caligan Partners LP potentially deemed a director by deputization, indicating a relationship between the director, the investment firm, and the company.

Stakeholder Impact

• Shareholders: Potential for minor dilution upon option exercise, but also benefit from incentivized director performance.
• Employees: The grant is part of an equity incentive plan, which generally benefits employees and management by aligning their interests with company performance.

Next Steps

• The options will vest on May 29, 2026, subject to David Johnson's continuous service.

Key Dates

Keywords

Exelixis, EXEL, Form 4, SEC filing, stock options, equity incentive plan, director compensation, beneficial ownership, insider transaction, Caligan Partners